Argan, Inc. enters its fiscal-quarter earnings release — scheduled for September 3 — with a stock that has been in freefall, options traders turning less defensive, and short sellers quietly adding to positions against the tide of a dramatic selloff.
The price action alone demands attention. AGX closed at $404.75 on September 1, down 10% on the week and 29% over the past month from what had been a standout year-to-date rally of more than 100%. That kind of drawdown concentrates minds heading into a print, and the interesting question is whether the market has already repriced sufficiently or whether shorts sense more to come.
Short positioning has been rebuilding, though it is not yet extreme. SI as a percentage of the free float climbed to 7.1%, up 6.6% on the week — a meaningful step-up that reverses a month-long drift lower. Looking at the history, short interest bottomed in early August around 807,000 shares and has since climbed back toward the mid-August peak of roughly 995,000. That recovery in shorts, happening into the selloff rather than ahead of it, suggests the bears are following price lower rather than leading it. The borrow market itself tells a relaxed story: cost to borrow is running at just 0.41%, near a 30-day low, and availability is extremely loose at 2,618% — roughly 26 shares available for every one currently lent out. There is no squeeze pressure here, and no shortage of borrow for anyone wanting to press the short. Options are showing the opposite of defensive positioning: the put/call ratio has dropped to 1.14, about 1.3 standard deviations its 20-day average of 1.27. After weeks of elevated put buying through July, that ratio has unwound sharply — a possible sign that near-term hedges have expired or been closed, rather than fresh optimism.
The Street's read on AGX is complicated by stale data. The most recent analyst action in the dataset dates to early June, when Lake Street raised its target to $600 from $375 while maintaining a Hold rating — a reaction to the prior quarter's print that drove a modest 1.2% next-day gain before the stock gave back over 9% in the following five days. Goldman Sachs had lifted its target to $518 back in late March. With the stock now at $405 and the mean analyst target at $680, the implied upside looks substantial on paper — but both targets predate the 29% drawdown and should be treated with caution until post-print updates arrive. The valuation multiple that has moved most noticeably is price-to-book, which has compressed by about 0.65 points over the past 30 days to 8.5x, while the trailing PE has pulled back to 31.4x. The ORTEX short score of 42.7 ranks in the 28th percentile for short pressure — not a crowded short by any stretch — and the dividend score sits at a striking 96th percentile, though the dividend history in the data is stale, last showing a $0.25 quarterly payment from mid-2022, so that factor score likely reflects something more current not captured here.
One ownership note worth flagging: a director, Jeffrey John Ronald Jr., sold 5,716 shares at $579.64 on July 31 — a $3.3 million open-market sale executed without a 10b5-1 plan, at a price roughly 43% above where the stock closed this week. That sale, the most recent insider transaction in the data, now looks like near-perfect timing. On the institutional side, BlackRock lifted its stake to 14.3% per a Schedule 13G/A filed in April, and Vanguard Portfolio Management crossed the 5% threshold in a July filing. No 13D activists are on the register. The disclosure caveat applies: these are event-driven filings around the 5% threshold, and positions may have changed since. Among correlated peers, the week's damage to AGX dwarfs the sector broadly — LGN fell 9.9% and IESC dropped 4%, but PWR and FIX closed nearly flat, suggesting the AGX selloff has a company-specific rather than purely sector-driven character.
The September 3 earnings release is now the only event that matters: whether the quarter can explain — or deepen — a 29% drawdown that the shorts are cautiously endorsing but the options market is no longer aggressively hedging.
See the live data behind this article on ORTEX.
Open AGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
